Market Size and Growth
The Global Rare Disease Genetic Testing Market reached USD 1.18 billion in 2025 and is projected to witness lucrative growth by reaching up to USD 3.29 billion by 2033. The global rare disease genetic testing market is expected to exhibit a CAGR of 13.7% during the forecast period (2026-2033). The rare disease genetic testing market is a growing sector within the healthcare industry. It involves the analysis of a person's DNA to identify genetic variations associated with rare diseases.
The market is characterized by a high level of competition and innovation, with companies offering a wide range of genetic testing services and solutions.
The global rare disease genetic testing market is projected to experience significant growth in the coming years, fueled by increasing awareness, supportive government initiatives and the expanding scope of precision medicine.
The global rare disease genetic testing market is driven by the factors such as the increasing prevalence of rare diseases, advancements in genetic sequencing technologies, growing awareness of rare diseases, increasing demand for expansion of precision medicine and increasing research and developments in rare disease genetic testing.
Market Scope
| Metrics | Details |
| CAGR | 13.7% |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (USD ) |
| Segments Covered | Disease Type, Technology, Specialty and End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To Know More Insights: Download Sample
Market Dynamics
Increasing Research and Developments Drive the Growth of the Rare Disease Genetic Testing Market
The research and development efforts contribute to the development of new and improved genetic testing technologies and methodologies. These advancements lead to more accurate, reliable and comprehensive tests, enhancing diagnostic capabilities for rare diseases. Innovative testing methods, such as whole-genome sequencing and gene panel testing, are continuously being developed, expanding the range of diseases that can be identified and increasing the market demand.
Research and Development initiatives help identify and characterize new genetic variations associated with rare diseases. Through extensive research and genomic studies, scientists can uncover previously unknown genetic mutations and markers that contribute to rare diseases. The identification of these genetic variations enables the development of targeted tests and treatments, driving the demand for genetic testing services.
For instance, on August 02, 2022, the Karnataka government launched the research and training unit for rare diseases here to further strengthen diagnosis, counseling and treatment, including developing a service facility for prenatal diagnosis for early identification of genetic disorders in pregnancy.
Increasing Demand for the Expansion of Precision Medicine Also Drives the Growth of the Rare Disease Genetic Testing Market
Precision medicine aims to provide personalized treatment strategies tailored to an individual's genetic profile. Genetic testing plays a crucial role in identifying genetic variations associated with rare diseases, enabling healthcare providers to develop personalized treatment plans. The demand for genetic testing services to guide precision medicine interventions drives the growth of the rare disease genetic testing market.
Genetic testing results help identify specific genetic mutations or variations that drive rare diseases. This information is instrumental in the development of targeted therapeutics designed to address the underlying genetic abnormalities. As precision medicine advances, there is an increasing need for accurate and comprehensive genetic testing to identify suitable candidates for targeted therapies, contributing to market growth.
For instance, on June 5, 2023, Dante Genomics, a global leader in genomics and precision medicine, announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing. The Rare Disease Health Package includes pre- and post-telemedicine consultations, providing access to specialists who may not be available in a patient's area. Dante removes financial barriers to care by identifying potential treatments and management strategies for rare diseases.
The High Cost of Genetic Testing Will Hamper the Growth of the Rare Disease Genetic Testing Market.
The high cost of genetic testing can make it financially burdensome for individuals, particularly those without adequate insurance coverage or limited financial resources. In some cases, the out-of-pocket expenses associated with genetic testing may be prohibitively high, deterring individuals from seeking testing services. This affordability barrier can restrict the market's growth potential and limit access to genetic testing for rare diseases.
Market Segment Analysis
The global rare disease genetic testing market is segmented based on disease type, technology, specialty, end user and region.
The Next-Generation Sequencing Technology Segment Accounted for Approximately 35.3% of the Rare Disease Genetic Testing Market Share
The next-generation sequencing technology enables the simultaneous analysis of multiple genes or the entire genome, providing a comprehensive view of an individual's genetic makeup. It allows for high-throughput sequencing, enabling the analysis of a large number of samples efficiently. The ability to generate vast amounts of sequencing data cost-effectively makes NGS a preferred choice for rare disease genetic testing.
For instance, in April 2023, Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the launch of NEW CentoGenome, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.
Next-generation sequencing technology facilitates the development of gene panels, exome sequencing and whole-genome sequencing, which cover a wide range of rare diseases. These testing approaches comprehensively assess genetic variations associated with rare diseases, allowing for accurate and efficient diagnosis. The versatility and flexibility of NGS in addressing different rare diseases contribute to its market dominance.
For instance, in March 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data for rare genetic diseases.
Market Geographical Share
North America Accounted for Approximately 40.7% of the Market Share in 2022, Owing to the Rising Prevalence and Increasing Research and Development Activities
North America has witnessed an increase in the prevalence of rare diseases, driving the demand for genetic testing services. Factors such as improved disease recognition, advanced healthcare infrastructure and increased awareness among healthcare providers and patients have contributed to the identification and diagnosis of rare diseases, thereby boosting the market for genetic testing.
North America has a well-established research and development ecosystem, with a strong focus on rare diseases. Academic institutions, research organizations and biotechnology companies in the region actively engage in research and clinical trials to expand the understanding of rare diseases and develop new testing methodologies. This emphasis on R&D drives market growth and fuels innovation in rare disease genetic testing.
Market Players
The major global players in the rare disease genetic testing market include Quest Diagnostics Inc, Arup Laboratories, Strand Life Sciences, Ambry Genetics, 3billion, Inc., Macrogen Inc, Color Genomics Inc, Centogene NV, Invitae Corporation and Myriad Genetics Inc.
Key Developments
- On April 14, 2026, government-led initiatives such as the NHS England Rare Diseases Action Plan emphasized expanding genomic screening programs and early diagnosis strategies. The plan supports integrating genetic testing into routine newborn screening to enable early detection and treatment of rare genetic disorders, improving patient outcomes and accelerating adoption of advanced diagnostic technologies.
- On March 23, 2026, pilot programs supported by Novartis AG and public health authorities introduced routine newborn screening for rare genetic conditions such as spinal muscular atrophy (SMA). This initiative highlights the growing importance of early genetic testing in reducing diagnostic delays and improving treatment success rates across rare diseases.
- On February 24, 2026, leading players including Illumina Inc., F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc. announced continued investments in next-generation sequencing (NGS) and genetic testing platforms. These advancements are driving precision medicine and enabling more accurate identification of rare genetic disorders globally.
- On January 2026, global healthcare systems reported increasing adoption of AI-powered genetic diagnostic tools to accelerate rare disease detection. Integration of machine learning with genomic sequencing is reducing diagnostic timelines and improving accuracy, particularly for complex and previously undiagnosed conditions.
- On October 2025, Illumina Inc. expanded its sequencing capabilities and partnerships to support large-scale genomic screening programs. The initiative focuses on improving accessibility and affordability of genetic testing for rare diseases across emerging markets.
- On May 25, 2025, researchers introduced a breakthrough rapid genetic testing method capable of diagnosing thousands of rare diseases within days using minimal blood samples. This innovation significantly reduces diagnostic delays and eliminates the need for invasive procedures, improving patient care pathways.
Why Purchase the Report?
- To visualize the global rare disease genetic testing market segmentation based on disease type, technology, specialty, end-user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of rare disease genetic testing market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Rare Disease Genetic Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.
